Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab

As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD) increases, the therapeutic armamentarium for its treatment can expand, and novel target therapies join the treatment pipeline. Interleukin (IL)-12 and IL23 are two key cytokines responsible for promoting and perpet...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Daniela, Privitera, Giuseppe, Fiorani, Marcello, Parisio, Laura, Calvez, Valentin, Papa, Alfredo, Gasbarrini, Antonio, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201364/
https://www.ncbi.nlm.nih.gov/pubmed/35721840
http://dx.doi.org/10.1177/17562848221102283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201364/
https://www.ncbi.nlm.nih.gov/pubmed/35721840
http://dx.doi.org/10.1177/17562848221102283

Ejemplares similares